Anticancer activity of streptochlorin, a novel antineoplastic agent, in cholangiocarcinoma
Open Access
- 1 April 2015
- journal article
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 9, 2201-2214
Abstract
Background: The aim of this study is to investigate the anticancer activity of streptochlorin, a novel antineoplastic agent, in cholangiocarcinoma. Methods: The anticancer activity of streptochlorin was evaluated in vitro in various cholangiocarcinoma cell lines for apoptosis, proliferation, invasiveness, and expression of various protein levels. A liver metastasis model was prepared by splenic injection of HuCC-T1 cholangiocarcinoma cells using a BALB/c nude mouse model to study the systemic antimetastatic efficacy of streptochlorin 5 mg/kg at 8 weeks. The antitumor efficacy of subcutaneously injected streptochlorin was also assessed using a solid tumor xenograft model of SNU478 cells for 22 days in the BALB/c nude mouse. Results: Streptochlorin inhibited growth and secretion of vascular endothelial growth factor by cholangiocarcinoma cells in a dose-dependent manner and induced apoptosis in vitro. In addition, streptochlorin effectively inhibited invasion and migration of cholangiocarcinoma cells. Secretion of vascular endothelial growth factor and activity of matrix metalloproteinase-9 in cholangiocarcinoma cells were also suppressed by treatment with streptochlorin. Streptochlorin effectively regulated metastasis of HuCC-T1 cells in a mouse model of liver metastasis. In a tumor xenograft study using SNU478 cells, streptochlorin significantly inhibited tumor growth without changes in body weight when compared with the control. Conclusion: These results reveal that streptochlorin is a promising chemotherapeutic agent to the treatment of cholangiocarcinoma.Keywords
This publication has 35 references indexed in Scilit:
- Pathogenesis, Diagnosis, and Management of CholangiocarcinomaGastroenterology, 2013
- New and emerging treatment options for biliary tract cancerOncoTargets and Therapy, 2013
- CholangiocarcinomaCritical Reviews in Oncology/Hematology, 2009
- CholangiocarcinomaHepatology, 2008
- Diagnosis and management of cholangiocarcinomaCurrent Gastroenterology Reports, 2008
- Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomasCancer Chemotherapy and Pharmacology, 2007
- Impact of Classification of Hilar Cholangiocarcinomas (Klatskin Tumors) on the Incidence of Intra- and Extrahepatic Cholangiocarcinoma in the United StatesJNCI: Journal of the National Cancer Institute, 2006
- Advances in the diagnosis, evaluation and management of cholangiocarcinomaCurrent Opinion in Gastroenterology, 2006
- Current approaches to the diagnosis and treatment of cholangiocarcinomaCurrent Gastroenterology Reports, 2006
- Cholangiocarcinoma: Molecular targeting strategies for chemoprevention and therapyHepatology, 2005